Shares of Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $30.01 and traded as high as $30.81. Ipsen shares last traded at $30.81, with a volume of 277 shares changing hands.
Ipsen Stock Up 1.8 %
The company’s 50 day moving average is $31.96 and its 200-day moving average is $30.01.
About Ipsen
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Read More
- Five stocks we like better than Ipsen
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Using the MarketBeat Dividend Yield Calculator
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.